Pular para o conteúdo principal
Ranking Invest

INCY - Incyte Corporation

Segmento: HealthcareIncyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Análise Ranking Invest

Valuation estimado
$ 8.33 Bi
Valor de Mercado
$ 24.62 Bi
Sobrepreço (AV)+195.4%
IVR
0.34A companhia vale 0,34 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.10O valuation alternativo equivale a 10% do valor de mercado da companhia.
MLL
0.10O lucro líquido dos controladores em 16 trimestres equivale a 10% do valor de mercado.
Último Balanço Atualizado: 1T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 5.62 Bi

Dívida Líquida

-$ 3.46 Bi

L4T

$ 1.43 Bi

MM4T

27.02%

Indicadores Básicos

ROE

25.46%

Índices de Previsibilidade

Receita Líquida

C0.07

Lucro

C0.43

Margem

C0.37

Índices de Tendência

Receita Líquida

B10.49

Lucro

A9.36

Margem

B7.39

Índices de Endividamento

DIV/PAT

-0.62

DIV/L4T

-2.42

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.